New FDA Guidance Announced

On July 31, the Food and Drug Administration (FDA) announced that it will be issuing a risk-based regulatory framework for the review, approval and post-market reporting requirements of laboratory developed tests—molecular diagnostic and genetic tests used to guide medical treatment—later this year. The Ovarian Cancer National Alliance has monitored this issue closely, and today released the following statement from Alliance CEO Calaneet Balas (expand to view statement).

Personalized Medicine Roundtable

The House Energy and Commerce Committee today convened a roundtable discussion on personalized medicine as part of the committee’s 21st Century Cures initiative. Laura M. Koontz, PhD, Director of Policy at the Ovarian Cancer National Alliance, was invited to participate in the roundtable and share the Alliance’s perspective on personalized medicine and ovarian cancer.

National Conference

Thank you to everyone who joined us in Washington, DC, for the 2014 Ovarian Cancer National Conference! We hope you left the meeting feeling inspired and connected to our community!

Supreme Court Ruling

A recent Supreme Court ruling in two cases could make it more difficult for women to access oral contraceptives, which are proven to reduce a woman’s risk of ovarian cancer.

Partner Member Profile

When her ovarian cancer recurred in 2010, Jean Ebert sought treatment in Chapel Hill, North Carolina. She soon connected with another woman who had been diagnosed around the same time—2008—with the same stage of ovarian cancer. Jean and Charlotte quickly formed a connection. “She wanted to do something and I wanted to do something,” recalls Jean. “We had the means to eat well and spend time restoring ourselves, but there were so many women who had many more things on their plates than just dealing with ovarian cancer.